Group items tagged

NHS England has commissioned the Royal Pharmaceutical Society (RPS) to develop guidance that helps community and hospital pharmacy teams across Britain to reduce the impact of pharmacy services, pharmaceutical care and medicines on the environment. The RPS said the Greener Pharmacy Guidance will enable pharmacies to self-assess their impact against the standards, benchmark and improve through evidence-based activities and actions. "I'm delighted our strong commitment to helping pharmacy reduce its environmental impact can now be taken to the next level through developing guidance and accreditation for pharmacy teams," RPS president Professor Claire Anderson said. "Medicines account for 25 per cent of carbon emissions within the NHS and this initiative underscores our commitment to promoting sustainable healthcare and supporting the NHS's goal of achieving 'net zero' emissions by 2040." Peter Morgan, medicines assistant director at NHS England, commented: "Pharmacy staff are involved in the purchasing and dispensing of almost every medicine used in the NHS and the new Greener Pharmacy Guidance and Self-accreditation scheme will provide support for pharmacy professionals by outlining clear actions to deliver more environmentally sustainable pharmacy practices." The RPS said the guidance and digital self-assessment toolkit will integrate with carbon calculator tools to help pharmacy teams to measure their carbon footprint, action plan to reduce use of carbon and improve sustainability.

The Royal Pharmaceutical Society (RPS) and Pharmacy Declares are inviting pharmacy teams from around the world to sign up and commit to taking "bold action" on climate change as mentioned in a climate change charter which was published on Monday (June 13). The charter asks pharmacy teams to commit to understanding how human health and the systems which underpin it are "reliant on the state of our natural environment" and actively explore ways to make pharmacy practice and medicine use more sustainable. It also asks to collaborate and share best practice to improve sustainability in pharmacy and healthcare; demonstrate leadership on sustainability or being a champion for sustainability at work; and assist patients to optimise their medicine use to increase both health outcomes and environmental sustainability. The individuals can also commit to a personal action on climate change of their own choosing. The Charter is being supported by a strong coalition of organisations from across pharmacy including the Centre for Postgraduate Pharmacy Education, the Clinical Pharmacy Association, College of Mental Health Pharmacy and Guild of Healthcare Pharmacists.

To maximise the benefits of the Pharmacy First service for patients, the NHS, and community pharmacies, Community Pharmacy England (CPE) has advised the community pharmacists to to establish a robust relationship between community pharmacies and local general practices. The news comes after several reports highlighted issues regarding GP referrals for the seven minor ailment conditions under the Pharmacy First services. According to the reports, many pharmacists claimed that "many GPs in England are not sending patients to them to be treated - and that some are refusing to participate at all in the "groundbreaking" Pharmacy First scheme". In response to foster better relationship with the GPs, CPE has said that strong local collaborations will enable general practice teams to confidently refer patients to the Pharmacy First and other community pharmacy services where appropriate. Moreover, the organisation emphasised implementation of long-term changes in practice will take time. The current focus on integrating GP referrals to Pharmacy First will likely require sustained effort over several months or longer.

The National Pharmacy Association (NPA) has announced that the Chief Pharmaceutical Officer for England, David Webb will be among the keynote speakers at the Pharmacy Odyssey Conference on 13 October. He and other special guests will discuss the future of community pharmacy within the NHS, during a day of insight and practical advice for pharmacy teams. The NPA promises expert opinion on the current pressures in the sector and a thorough exploration of the long-term picture. NPA Director of Membership, Simon Tebbutt, explains: "With the NPA centenary in 2021 behind us, this will be a foray into the future - mapping the coming decade, and next half-century - as well as covering the many challenges of the present time." The theme of the conference, to be held online and sponsored by Novo Nordisk, is Pharmacy Odyssey: Services, Supply and Sustainability.

The business landscape worldwide is undergoing a significant transformation, shifting from a sole focus on profitability to incorporating a broader spectrum of considerations. Today, Environmental, Social, and Governance (ESG) criteria are integral to business operations, reflecting a commitment to sustainable and ethical practices alongside financial growth. ESG stands for three interconnected pillars: Environmental, focusing on reducing a company's ecological footprint; Social, addressing the impact on employees, diversity, equity, inclusion, and the broader community; and Governance, which ensures responsible management practices, ethical behavior, and compliance with regulations. This holistic approach is becoming a critical foundation for long-term success in various industries, including healthcare. For the UK healthcare and pharmacy sectors, integrating ESG not only aligns with global sustainability goals but also offers substantial benefits. This article delves into the specific implications of ESG for UK pharmacies, highlighting how they can leverage these practices to foster both community well-being and business success.

The General Pharmaceutical Council (GPhC) and the Chief Pharmaceutical Officer for England have written a letter to pharmacy professionals thanking them for providing the best possible services to patients and the public, despite experiencing high and sustained demands and pressures. GPhC Chief Executive Duncan Rudkin and CPhO David Webb indicated that there will be further challenges over the coming weeks and months due to the ongoing industrial action, and staff shortages due to sickness or caring responsibilities. They expressed concerned that increased pressure will have a significant and potentially prolonged impact on pharmacy teams both personally and professionally. Acknowledging that pharmacy professionals may have to make some difficult decisions as they deal with the pressures they face, the leaders have urged those working in pharmacy to use "your professional judgement to assess and mitigate risk, and to deliver safe and effective care for your patients within your scope of practice."

The Pharmaceutical Services Negotiating Committee (PSNC)'s members are seeking immediate rescue packages for the sector to help with energy bills and to ease capacity constraints. In a meeting held on 14th and 15th September, the committee members expressed their anger and frustration on the reluctance of NHS England and government to fund pharmacy sustainably. The meeting was held to consider practical steps to ease the pressures on the community pharmacy sector, and to oversee the progress of negotiations on the Community Pharmacy Contractual Framework (CPCF) and other work. Committee members, as pharmacy contractors, shared their experiences of the current pressures on all contractors, including the inability to deliver some services and to maintain core service levels; the capacity and workforce crises facing the sector; the critical need for funding support this winter; and the urgent need for Government to adapt the Price Concessions system to meet the needs of contractors. "The Price Concessions system is no longer working for contractors in the current volatile medicine supply environment and PSNC is clear this is not acceptable," said the committee.

Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading academics in human behaviour and frontline healthcare professionals including community pharmacists. Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges. Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an independent, global leader in consumer health. The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change. The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice. Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work. "We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t

Pharmacies and other spaces should be able to facilitate the provision of health care to bring services closer to patients and reduce demands on general practice, suggested a report by Tony Blair Institute. In a paper 'Modern and Sustainable NHS Providing Accessible and Personalised Care for All', it has propose six areas for reform where radical-but-practical policy action will begin to transform the future of the NHS and deliver better patient care. It has proposed to create new access routes for services and providers. It added: "The range and availability of health-care services must increase to reflect citizens' demands and their increasingly complex needs. "Pharmacies, gyms, supermarkets, workplaces and other spaces should all be able to provide or facilitate the provision of health care, bringing services closer to patients and reducing demands on general practice. It suggested: "We must move towards greater community-based care and the creation of a neighbourhood health service, with more routes for direct patient access, to ensure services are available when and where people need them. These should all be accessible through a single, simple digital front door to the NHS."

Thanks to increasing environmental awareness among people worldwide, there's a growing commitment to sustainable practices across industries. The healthcare sector, including pharmacies, is no exception. Recognising the fact that 'climate crisis is a health crisis', 124 countries signed a new Declaration on Climate and Health at the first-ever Health Day at the United Nations climate change conference, COP28 Dubai, which was held on 3 December 2023. The declaration acknowledged the need to prepare healthcare systems to cope with climate change and accelerate actions to protect communities. Welcoming the declaration, Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO) emphasized the need to build "climate-resilient and low-carbon" health systems to protect the health of both the planet and people. Pharmacies play a crucial role in providing essential medications and healthcare services to the community, but their operations can have environmental implications.

Members of the Royal Pharmaceutical Society (RPS) highlighted the work of pharmacists in making medicines use and the whole NHS more environmentally sustainable at the Welsh Senedd this week. Politicians present were informed that around 25 per cent of the NHS' carbon emissions result from medicines use, and therefore pharmacists' expert skills are crucial for reducing these emissions. RPS Wales Director, Elen Jones, was among the RPS staff who attended the event, which was co-hosted with the Association of the British Pharmaceutical Industry. Commenting on the event, Elen said: "It was great to get so many productive conversations with the politicians to highlight the great work pharmacists are already doing in the sustainability field and to explain what further steps are required to reduce the negative environmental and ecological impact of medicines."

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical Industry (ABPI). The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI. In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI. All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while also supporting economic growth for the UK.

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."